COMMUNIQUÉS West-GlobeNewswire

Glass House Brands and Eaze Partner to Launch PLUS Cannabis Gummies in Florida
10/04/2025
LONG BEACH, Calif. and TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
10/04/2025
– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE [...]
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
10/04/2025
Highlights will include data from non-clinical and real-world patient use BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies [...]
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
10/04/2025
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
10/04/2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple [...]
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
10/04/2025
– SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT’s) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ( [...]
Large Reductions in Suicide Risk, Attempts and Deaths Demonstrated by Three “Real World” Studies in Primary Care
10/04/2025
Shatterproof and The Bowman Family Foundation call for widescale adoption of Collaborative Care Model in primary care to reduce suicide rates and lower total healthcare costs for payers NORWALK, Conn., April 10, 2025 ( [...]
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
10/04/2025
LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of [...]
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
10/04/2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
10/04/2025
On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic [...]
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
10/04/2025
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety [...]
Dr. Mahmoud Aljurf, First Non-US Physician to win Weinberger Prize by American College of Physicians
10/04/2025
KFSHRC's pioneer recognised for groundbreaking work in hematology and stem cell research RIYADH, Saudi Arabia, April 10, 2025 (GLOBE NEWSWIRE) -- Dr. Mahmoud Aljurf, M.D., MACP, Director of the Adult Stem Cell [...]
Merakris Therapeutics Appoints Roger Ilagan to Chief Scientific Officer
10/04/2025
As CSO, Dr. Ilagan will continue to spearhead the advancement of cell-free biologic therapies from immunologically privileged tissues to regenerative medicine drugs for complex cutaneous wounds RESEARCH TRIANGLE PARK, N [...]
The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
10/04/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 10 APRIL 2025 at 13.15 EEST The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to [...]
Keros Therapeutics Announces Review of Strategic Alternatives
10/04/2025
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage [...]
Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
10/04/2025
The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET [...]
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
10/04/2025
ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 [...]
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
10/04/2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025
10/04/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7AM CET Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025 Fagron, the [...]

Pages